Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
UF Innovate | Sid Martin Biotech resident client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced the enrollment of the 60th patient in its Phase 2 double-blind, placebo-controlled clinical trial of AG013.
AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactisbacteria strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. The trefoil factor family (TFF) is a family of three different peptides secreted by epithelial cells of the gastrointestinal tract in response to injury (Hoffman, 2004). Their presence has been implicated in reducing chemotherapy- and radiation-induced injury, both in preclinical studies (Beck et al., 2004) and in clinical trials (Peterson et al., 2009).
Learn more about Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial.